Literature DB >> 14760153

Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia.

M J Schultz1, J Millo, M Levi, C E Hack, G J Weverling, C S Garrard, T van der Poll.   

Abstract

BACKGROUND: Fibrin deposition is a hallmark of pneumonia. To determine the kinetics of alterations in local coagulation and fibrinolysis in relation to ventilator associated pneumonia (VAP), a single centre prospective study of serial changes in pulmonary and systemic thrombin generation and fibrinolytic activity was conducted in patients at risk for VAP.
METHODS: Non-directed bronchial lavage (NBL) was performed on alternate days in patients expected to require mechanical ventilation for more than 5 days. A total of 28 patients were studied, nine of whom developed VAP.
RESULTS: In patients who developed VAP a significant increase in thrombin generation was observed in the airways, as reflected by a rise in the levels of thrombin-antithrombin complexes in NBL fluid accompanied by increases in soluble tissue factor and factor VIIa concentrations. The diagnosis of VAP was preceded by a decrease in fibrinolytic activity in NBL fluid. Indeed, before VAP was diagnosed clinically, plasminogen activator activity levels in NBL fluid gradually declined, which appeared to be caused by a sharp increase in NBL fluid levels of plasminogen activator inhibitor 1.
CONCLUSION: VAP is characterised by a shift in the local haemostatic balance to the procoagulant side, which precedes the clinical diagnosis of VAP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14760153      PMCID: PMC1746934          DOI: 10.1136/thorax.2003.013888

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  18 in total

1.  Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects.

Authors:  P W Friederich; M Levi; K A Bauer; G P Vlasuk; W E Rote; D Breederveld; T Keller; M Spataro; S Barzegar; H R Büller
Journal:  Circulation       Date:  2001-05-29       Impact factor: 29.690

2.  The yin and yang of fibrin in the airways.

Authors:  J A McDonald
Journal:  N Engl J Med       Date:  1990-03-29       Impact factor: 91.245

3.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome.

Authors:  P Bertozzi; B Astedt; L Zenzius; K Lynch; F LeMaire; W Zapol; H A Chapman
Journal:  N Engl J Med       Date:  1990-03-29       Impact factor: 91.245

5.  Quantitation of urokinase antigen in plasma and culture media by use of an ELISA.

Authors:  D J Binnema; J J van Iersel; G Dooijewaard
Journal:  Thromb Res       Date:  1986-09-01       Impact factor: 3.944

Review 6.  Regulatory role of cytokines in disseminated intravascular coagulation.

Authors:  T van der Poll; E de Jonge; M Levi
Journal:  Semin Thromb Hemost       Date:  2001-12       Impact factor: 4.180

7.  A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma.

Authors:  J H Verheijen; E Mullaart; G T Chang; C Kluft; G Wijngaards
Journal:  Thromb Haemost       Date:  1982-12-27       Impact factor: 5.249

8.  Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia.

Authors:  Anita W Rijneveld; Sandrine Florquin; Paul Bresser; Marcel Levi; Vivian De Waard; Roger Lijnen; Jaring S Van Der Zee; Peter Speelman; Peter Carmeliet; Tom Van Der Poll
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

9.  Local activation of the coagulation and fibrinolysis systems in lung disease.

Authors:  B Nakstad; T Lyberg; O H Skjønsberg; N P Boye
Journal:  Thromb Res       Date:  1990-03-15       Impact factor: 3.944

10.  Procoagulant activity in bronchoalveolar lavage of severely traumatized patients--relation to the development of acute respiratory distress.

Authors:  W Seeger; J Hübel; K Klapettek; U Pison; U Obertacke; T Joka; L Roka
Journal:  Thromb Res       Date:  1991-01-01       Impact factor: 3.944

View more
  55 in total

1.  Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia.

Authors:  Florry E van den Boogaard; Cornelis van 't Veer; Joris J T H Roelofs; Joost C M Meijers; Marcus J Schultz; George J Broze; Tom van der Poll
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

2.  Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inflammation.

Authors:  Rogier M Determann; Julian L Millo; Chris S Garrard; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2006-04-14       Impact factor: 17.440

3.  Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury.

Authors:  Marcus J Schultz; Marcel Levi
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

4.  Association between urokinase haplotypes and outcome from infection-associated acute lung injury.

Authors:  John Arcaroli; Jeff Sankoff; Nianjun Liu; David B Allison; James Maloney; Edward Abraham
Journal:  Intensive Care Med       Date:  2007-11-10       Impact factor: 17.440

5.  Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans.

Authors:  Tom van der Poll; Marcel Levi; Jerry A Nick; Edward Abraham
Journal:  Am J Respir Crit Care Med       Date:  2005-03-04       Impact factor: 21.405

6.  Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation.

Authors:  Peter Dahlem; Albert P Bos; Jack J Haitsma; Marcus J Schultz; Joost C M Meijers; Burkhard Lachmann
Journal:  Intensive Care Med       Date:  2005-03-08       Impact factor: 17.440

7.  Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.

Authors:  Marcel Schouten; Koenraad F van der Sluijs; Bruce Gerlitz; Brian W Grinnell; Joris J T H Roelofs; Marcel M Levi; Cornelis van 't Veer; Tom van der Poll
Journal:  Crit Care       Date:  2010-04-14       Impact factor: 9.097

8.  Unfractionated heparin and enoxaparin reduce high-stretch ventilation augmented lung injury: a prospective, controlled animal experiment.

Authors:  Li-Fu Li; Chung-Chi Huang; Horng-Chyuan Lin; Ying-Huang Tsai; Deborah A Quinn; Shuen-Kuei Liao
Journal:  Crit Care       Date:  2009-07-06       Impact factor: 9.097

9.  Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury.

Authors:  Anil Sapru; Martha A Q Curley; Sandra Brady; Michael A Matthay; Heidi Flori
Journal:  Intensive Care Med       Date:  2009-10-24       Impact factor: 17.440

10.  Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats.

Authors:  Jorrit J Hofstra; Alexander D Cornet; Bart F de Rooy; Alexander P Vlaar; Tom van der Poll; Marcel Levi; Sebastian Aj Zaat; Marcus J Schultz
Journal:  Crit Care       Date:  2009-09-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.